European Project on Mendelian Forms of Parkinson s Disease
The Collaborative Project on Mendelian Forms of Parkinson’s Disease (MEFOPA) will bring together the major groups in Europe with a track-record in basic and clinical research on rare Mendelian forms of Parkinson’s disease (PD) in...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PARNANT
Pathogenetic pathways in age related neurodegenerations as n...
183K€
Cerrado
PID2019-109046GA-I00
REDES GENETICAS REGULADORAS EN LA ENFERMEDAD DE PARKINSON
143K€
Cerrado
SAF2009-10434
ANALISIS GENETICO DE ENFERMEDAD DE PARKINSON
387K€
Cerrado
NEURODOPA DEGEN
Elucidating mechanisms of dopaminergic neuronal degeneration...
75K€
Cerrado
SAF2017-89402-R
RELACION ENTRE LRRK2 Y EL DEFICIT DE TRAFICO VESICULAR MEDIA...
169K€
Cerrado
RECOLOR
Regulation and consequences of LRRK2 phosphorylation a path...
185K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The Collaborative Project on Mendelian Forms of Parkinson’s Disease (MEFOPA) will bring together the major groups in Europe with a track-record in basic and clinical research on rare Mendelian forms of Parkinson’s disease (PD) in order to identify and validate relevant disease-related molecular pathways, drug-targets and biomarkers for disease susceptibility and progression.. Over the last years it has become increasingly clear that progress in the understanding of the molecular basis of PD, the second most common neurodegenerative disorder, and hence the chance to develop effective disease-modifying treatments, will most likely be brought about by focusing on the rare variants of the disease with known genetic defects. The groups forming the MEFOPA-consortium will therefore analyze the molecular pathways underlying inherited forms of PD with autosomal-dominant and autosomal-recessive inheritance in an integrative way, using cellular and animal models and cutting-edge technology. These two subprojects will provide targets for novel, disease-modifying treatment strategies. In a third subproject, a European registry and biobank for patients with rare Mendelian forms of PD will be established. Body fluids will be collected and systematically analyzed by unbiased proteomic techniques as well as by focussed analysis of candidate proteins, and ex vivo cellular models will be generated, in order to allow validation of disease-related alterations detected in the models analyzed in subprojects 1 and 2. Through this integrated, translational approach combining basic and clinical research groups, the project aims to achieve measurable progress in defining the relevant targets and readouts for disease-modifying therapies and will set the stage for rationally designed drug trials in carefully selected groups of patients and even presymptomatic mutation carriers.